CJC-1295 (No DAC) / Mod GRF 1-29 (2mg)
CJC-1295 without DAC (known as Mod GRF 1-29) is a modified GHRH analog with a half-life of ~30 minutes, often used in combination with GHRP peptides. 2 mg vial.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full CJC-1295 encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
Mod GRF 1-29 stimulates the GHRH receptor in the pituitary gland, triggering pulsatile secretion of growth hormone. Unlike CJC-1295 DAC, the short half-life preserves the natural pulsatile pattern.
Quick Start
- Reconstitution: Add 1.0 mL bacteriostatic water → 2.0 mg/mL concentration.
- Typical dose: 100 mcg per injection, 1–3× daily.
- Storage: −20 °C (powder); 2–8 °C (solution).
Typical Approach (1 mL = 2.0 mg/mL)
Route: Subcutaneously | Frequency: 1–3× daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 100 mcg / dose | 5 Units (0.05 mL) |
| Weeks 3–12 | 100 mcg / dose | 5 Units (0.05 mL) |
1–3× daily, 100 mcg per injection (the bedtime dose first; then also morning or post-exercise). Often studied in combination with GHRP-2 or GHRP-6.
Related compounds
Reconstitution Steps
- Withdraw 1.0 mL bacteriostatic water.
- Inject slowly.
- Gently swirl.
- Refrigerate at 2–8 °C.
Protocol Overview
- Goal: Enhance natural growth hormone secretion.
- Schedule: 100 mcg 1–3× daily for 8–12 weeks.
Dosing Protocol
- Dose: 100 mcg per injection.
- Frequency: 1×/day before bed (Wks 1–2), then 2–3×/day.
- Combo: With GHRP-2 or Ipamorelin 100 mcg.
- Cycle: 8–12 weeks.
- Break between cycles: 4-week break before the next cycle.
Washout & Cycle Restart
When can I restart?
4-week break before the next cycle.
Minimum wait period: 4 weeks
Storage Instructions
- Powder: −20 °C.
- Solution: 2–8 °C, use within 21 days.
Important Notes
- Short half-life (~30 minutes) — requires multiple daily doses.
- Acts synergistically with GHRP peptides.
- Do not administer near meals (fat inhibits GH).
Potential Benefits & Side Effects
Potential Benefits:
- Physiological pulsatile GH secretion.
- Synergy with GHRP peptides.
- Improved protein synthesis and recovery.
Potential Side Effects:
- Injection site redness.
- Sensation of warmth/flushing.
- Fluid retention (rare).
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical risk (GH/IGF-1 elevation)
Without DAC, GH elevation is more physiological (pulsatile). Theoretical concern with long-term use.
📄 J Clin Endocrinol Metab 2006References
- J Clin Endocrinol Metab — GHRH analogues and GH secretion
View Source - Growth Horm IGF Res — Modified GRF 1-29 pharmacokinetics
View Source
Recommended Supplements
L-Arginine + L-Ornithine
ZMA (Zinc + Magnesium + B6)
External Sources & Regulatory Status
Regulatory Approvals
Research-only — Modified GRF(1-29)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →